BR112015019223A2 - método para prolongar a longevidade de um indivíduo; método para diminuir os níveis de glicose e/ou igf-1 em um indivíduo; método para aliviar um sintoma de quimiotoxicidade em um indivíduo; e método para tratar a quimiotoxicidade em um indivíduo - Google Patents

método para prolongar a longevidade de um indivíduo; método para diminuir os níveis de glicose e/ou igf-1 em um indivíduo; método para aliviar um sintoma de quimiotoxicidade em um indivíduo; e método para tratar a quimiotoxicidade em um indivíduo

Info

Publication number
BR112015019223A2
BR112015019223A2 BR112015019223A BR112015019223A BR112015019223A2 BR 112015019223 A2 BR112015019223 A2 BR 112015019223A2 BR 112015019223 A BR112015019223 A BR 112015019223A BR 112015019223 A BR112015019223 A BR 112015019223A BR 112015019223 A2 BR112015019223 A2 BR 112015019223A2
Authority
BR
Brazil
Prior art keywords
individual
chemotoxicity
levels
igf
alleviating
Prior art date
Application number
BR112015019223A
Other languages
English (en)
Portuguese (pt)
Inventor
Elyse Levine Morgan
brandhorst Sebastian
D Longo Valter
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of BR112015019223A2 publication Critical patent/BR112015019223A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
BR112015019223A 2013-02-12 2014-02-12 método para prolongar a longevidade de um indivíduo; método para diminuir os níveis de glicose e/ou igf-1 em um indivíduo; método para aliviar um sintoma de quimiotoxicidade em um indivíduo; e método para tratar a quimiotoxicidade em um indivíduo BR112015019223A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Publications (1)

Publication Number Publication Date
BR112015019223A2 true BR112015019223A2 (pt) 2017-07-18

Family

ID=51297596

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015019223A BR112015019223A2 (pt) 2013-02-12 2014-02-12 método para prolongar a longevidade de um indivíduo; método para diminuir os níveis de glicose e/ou igf-1 em um indivíduo; método para aliviar um sintoma de quimiotoxicidade em um indivíduo; e método para tratar a quimiotoxicidade em um indivíduo

Country Status (12)

Country Link
US (3) US9237761B2 (https=)
EP (2) EP2956776A4 (https=)
JP (2) JP6885671B2 (https=)
KR (1) KR20150124962A (https=)
CN (3) CN114236130A (https=)
AU (3) AU2014216349B2 (https=)
BR (1) BR112015019223A2 (https=)
CA (1) CA2900782C (https=)
ES (1) ES2807781T3 (https=)
MX (1) MX382484B (https=)
RU (2) RU2018141475A (https=)
WO (1) WO2014127000A2 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装
US9386790B2 (en) 2013-07-01 2016-07-12 University Of Southern California Fasting condition as dietary treatment of diabetes
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
EP3125904A4 (en) 2014-04-02 2017-08-30 University of Southern California Autoimmunity and multiple sclerosis treatment
AU2016219173B2 (en) 2015-02-12 2020-02-20 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
KR20180002677A (ko) * 2015-04-16 2018-01-08 유니버시티 오브 써던 캘리포니아 라파마이신 및 덱사메타손에 의해 유도된 표준 및 고 글루코스 조건에 대응하여 정상 세포를 보호하고 암 감작 조건을 생성하는 금식 모방 규정식(fmd) 및 글루코스 저하 약물
BR112017023748A2 (pt) * 2015-05-06 2018-07-31 University Of Southern California métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
CN108463121A (zh) * 2016-01-12 2018-08-28 南加利福尼亚大学 长期禁食模仿作为多发性骨髓瘤和其它癌症的膳食治疗的用途
KR20180120153A (ko) 2016-02-15 2018-11-05 유니버시티 오브 써던 캘리포니아 당뇨병 및 기타 질환 치료를 위한 배아형 재생을 자극하는 약물 조합물 및 방법
AU2017261723B2 (en) 2016-05-11 2023-02-09 University Of Southern California Fasting mimicking diet (FMD) as an immunoregulatory treatment for gastrointestinal autoimmune/inflammatory diseases.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
MX2020009613A (es) * 2018-03-15 2021-02-26 Univ Southern California Dieta que imita el ayuno (fmd) pero no ayuno solo con agua, promueve la reversion de la inflamacion y patologia de la enfermedad de intestino irritable (ibd).
AU2019280170B2 (en) * 2018-06-07 2024-03-28 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
WO2020015842A1 (en) 2018-07-18 2020-01-23 Michalsen Andreas Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
US20200147112A1 (en) * 2018-10-04 2020-05-14 Meiji Co., Ltd. Diet therapy of intractable cancer and medical diet suitable therefor
CA3119100C (en) 2018-11-09 2024-06-04 Valter D. Longo Nutrition bar for intermittent fasting-mimicking
CA3134756A1 (en) * 2019-04-30 2020-11-05 Valter D. Longo Fasting-mimicking diet (fmd) as an intervention for alzheimer's disease (ad)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
WO2021126968A1 (en) * 2019-12-16 2021-06-24 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
EP4076458A1 (en) 2019-12-19 2022-10-26 Leibniz-lnstitut Für Altersforschung Nad-precursors and dietary restriction for treating age-related medical conditions
IT202000008740A1 (it) 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
CN116096251A (zh) * 2020-09-23 2023-05-09 氨基维他有限公司 癌症的代谢疗法
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
TW202541716A (zh) * 2023-12-14 2025-11-01 美商艾爾 紐特拉公司 用於延長壽命、增強體力和機能的可食用產品及其食用和製造方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
AU2002320100A1 (en) * 2001-06-15 2003-01-02 Interleukin Genetics, Inc. Methods for detecting and treating the early onset of aging-related conditions
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
WO2006069918A1 (en) * 2004-12-27 2006-07-06 Nestec S.A. Use of infant formula with reduced protein content
WO2007088046A2 (en) * 2006-02-01 2007-08-09 Nestec S.A. Nutritional system and methods for increasing longevity
ES2800327T3 (es) * 2008-04-24 2020-12-29 Univ Of Southern California Usc Stevens Composiciones dietéticas y métodos de protección contra la quimioterapia o radioterapia
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
CA2779282C (en) * 2009-10-22 2017-12-05 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
CA2888811C (en) * 2012-10-22 2023-10-24 University Of Southern California A diet package, and uses thereof
CN114236130A (zh) * 2013-02-12 2022-03-25 南加利福尼亚大学 用于减轻年龄相关症状的膳食包装

Also Published As

Publication number Publication date
KR20150124962A (ko) 2015-11-06
AU2020200297A1 (en) 2020-02-06
HK1212028A1 (en) 2016-06-03
CN109187991A (zh) 2019-01-11
RU2018141475A3 (https=) 2022-03-29
RU2015134780A (ru) 2017-03-20
AU2014216349A1 (en) 2015-08-06
US9237761B2 (en) 2016-01-19
US20160331016A1 (en) 2016-11-17
RU2674681C2 (ru) 2018-12-12
ES2807781T3 (es) 2021-02-24
US20140227373A1 (en) 2014-08-14
CN105008929B (zh) 2018-10-02
CA2900782C (en) 2022-09-27
EP2956776A4 (en) 2016-12-21
JP6885671B2 (ja) 2021-06-16
EP3510875B1 (en) 2020-06-10
WO2014127000A2 (en) 2014-08-21
AU2014216349B2 (en) 2019-10-24
AU2020200297B2 (en) 2022-04-07
CN114236130A (zh) 2022-03-25
AU2022202764A1 (en) 2022-05-19
US20170035094A1 (en) 2017-02-09
CA2900782A1 (en) 2014-08-21
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
JP2020073473A (ja) 2020-05-14
EP2956776A2 (en) 2015-12-23
EP3510875A1 (en) 2019-07-17
MX382484B (es) 2025-03-13
JP2016509994A (ja) 2016-04-04
CN109187991B (zh) 2021-12-24
CN105008929A (zh) 2015-10-28

Similar Documents

Publication Publication Date Title
BR112015019223A2 (pt) método para prolongar a longevidade de um indivíduo; método para diminuir os níveis de glicose e/ou igf-1 em um indivíduo; método para aliviar um sintoma de quimiotoxicidade em um indivíduo; e método para tratar a quimiotoxicidade em um indivíduo
Kriegel et al. Does vitamin D affect risk of developing autoimmune disease?: a systematic review
BR112017007285A2 (pt) ?método e sistema para prever débito cardíaco contínuo (cco) de um paciente baseado em dados fisiológicos?
BR112013026447A2 (pt) métodos para a regulação da expressão de gene de sirtuína
Juárez et al. Revisiting the ‘Low BirthWeight paradox’using a model-based definition
Searle et al. Russel–Silver syndrome: A historical note and comment on an older adult
BR112014016135A8 (pt) uso de uma fórmula para lactentes com caloria reduzida contendo nucleotídeos e/ou carotenóides para reduzir os efeitos adversos à saúde em uma idade mais avançada
BR112017011949A2 (pt) placa óssea, conjuntos cirúrgicos e conjuntos de reconstrução
BR112015019778A2 (pt) Administração in ovo de fatores de crescimento para o aperfeiçoamento de desempenho de ave doméstica
Meng-Meng et al. Research advances in the association between maternal intake of methyl donor nutrients during pregnancy and DNA methylation in offspring
Parige et al. Enteral feeding during packed red blood cell transfusion in English neonatal units
Hasanpur et al. Association between early growth-related traits and ascites induced in broiler sire lines by saline drinking water or cool temperatures
Haxhire et al. < The> incidence of postoperative delirium in elderly patients undergoing urologic surgery
CHANG et al. Low protein diet for patients with chronic kidney disease
Hyanikyaynen et al. Psychological protection and approaches to psychotherapeutic correction of patients with chronic ischemia of a brain at an initial stage
MacLennan et al. Response to “Malignant Hyperthermia—human stress triggering” in reference to original article “Mechanistic models for muscle diseases and disorders originating in the sarcoplasmic reticulum” http://dx. doi. org/10.1016/j. bbamcr. 2010.11. 009
Conti et al. Estimação de parâmetros genéticos para peso corporal, ganho em peso e características morfométricas de tilápias do Nilo utilizando modelos de regressão aleatória
Iram Saddiqa et al. Chronic idiopathic urticaria; suggested/hypothetical role of elevated serum TSH in pathogenesis of chronic idiopathic urticaria
BR112014030243A2 (pt) métodos para diagnosticar doença valvular crônica
Nakai The Role of Pharmacists in the Japanese Integrated Community Care System
XIONG et al. Analysis of the anxiety situation and the influencing factors among gerontal patients with osteoporosis
Teles Correção da deformidade da cartilagem alar com cartilagem conchal em pacientes fissurados unilaterais
Snellman et al. Serum 25-hydroxyvitamin D in relation to BMD and fractures in a Swedish cohort of women and men
Behzad et al. Relationship between unexplained arthralgia and vitamin D deficiency: a case control study
Anwar et al. HLA class I and II genotyping by PCR-SSO in patients with type-1 diabetes mellitus

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements